APA (7th ed.) Citation

Anker, S. D., Butler, J., Filippatos, G. S., Jamal, W., Salsali, A., Schnee, J., . . . Gomez Mesa, J. E. (2019). Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: Rationale for and design of the EMPEROR‐Preserved Trial. European Journal of Heart Failure, 21(10), 1279. https://doi.org/10.1002/ejhf.1596

Chicago Style (17th ed.) Citation

Anker, Stefan D., et al. "Evaluation of the Effects of Sodium–glucose Co‐transporter 2 Inhibition with Empagliflozin on Morbidity and Mortality in Patients with Chronic Heart Failure and a Preserved Ejection Fraction: Rationale for and Design of the EMPEROR‐Preserved Trial." European Journal of Heart Failure 21, no. 10 (2019): 1279. https://doi.org/10.1002/ejhf.1596.

MLA (9th ed.) Citation

Anker, Stefan D., et al. "Evaluation of the Effects of Sodium–glucose Co‐transporter 2 Inhibition with Empagliflozin on Morbidity and Mortality in Patients with Chronic Heart Failure and a Preserved Ejection Fraction: Rationale for and Design of the EMPEROR‐Preserved Trial." European Journal of Heart Failure, vol. 21, no. 10, 2019, p. 1279, https://doi.org/10.1002/ejhf.1596.